Detail akcie Immucell Corp online

Business Summary: ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Financial Summary: BRIEF: For the three months ended 31 March 2025, ImmuCell Corp revenues increased 11% to $8.1M. Net income totaled $1.4M vs. loss of $438K. Revenues reflect Re-Tain segment increase of 5% to $39K, United States segment increase of 13% to $7.2M. Net Income reflects First Defense segment income increase of 55% to $2.5M, Re-Tain segment loss decrease of 48% to $698K.